Market
The latest in market for medical-aesthetics practice owners.
Market
Daewoong's NABOTA Enters Seventh Middle East Market
Korean toxin maker completes GCC sweep, signaling aggressive international distribution.
Market
Daewoong's Nabota Completes 7-Market GCC Sweep
Korean toxin reaches Kuwait, signaling aggressive Middle East expansion and global scale-up.
Market
GLP-1 Weight Loss Boom Lifts Galderma Aesthetics Sales 25%
CEO confirms GLP-1 users driving preventive and corrective aesthetics demand—practices should prepare for sustained volume and case-mix shifts.
Market
Daewoong's Nabota Enters Kuwait—Completes 7-Market GCC Sweep
Korean toxin expands across Middle East, signaling aggressive international push and competitive pressure on Allergan and Galderma in high-margin markets.
Market
Daewoong's Nabota Enters Kuwait—7th Middle East Market
South Korean toxin completes GCC footprint, signaling aggressive regional strategy beyond AbbVie and Galderma.
Market
Galderma Capitalizes on GLP-1 Weight-Loss Trend—What Practices Need to Know
As patients on semaglutide and tirzepatide seek facial rejuvenation, Galderma's H1 surge reflects the medspa industry's pivot to post-GLP-1 aesthetics.
Market
Daewoong's Nabota Hits 1 Trillion Won in Cumulative Sales—Asian Toxin Market Matures
South Korean botulinum toxin reaches milestone as Asian aesthetics market consolidates around regional players.
Market
"Ozempic Face" Facials Driving Botox Boom as GLP-1 Users Seek Preventive Aesthetics
Medspa demand for neuromodulators and skin-tightening treatments accelerates as GLP-1 patients proactively address volume loss.
Market
Galderma Capitalizes on GLP-1 Weight Loss Trend—What Practices Should Know
Rising demand for facial rejuvenation among patients on semaglutide and tirzepatide is driving injectable volume.
Market
Daewoong's Nabota Crosses 1 Trillion Won in Cumulative Sales—Asian Toxin Gains Scale
South Korean neuromodulator reaches major sales milestone, signaling sustained demand outside North America.
Market
"Ozempic Face" Facials Driving Botox Boom—Practices Capitalize on GLP-1 Side Effect
Practices are bundling neuromodulators, fillers, and skin treatments to address volume loss in GLP-1 patients.
Market
Galderma Capitalizes on GLP-1 Weight Loss Trend; 'Ozempic Face' Drives Filler and Toxin Demand
Rapid weight loss from semaglutide and tirzepatide is creating new patient demand for facial volume restoration and skin tightening.
Market
Hugel Launches Letybo in India — Expanding Asia-Pacific Footprint
South Korean toxin manufacturer enters India's growing aesthetic market as part of broader regional strategy.
Market
Hugel Launches Letybo in India, Targets 9% Market Share by 2026
South Korean toxin maker enters India's fast-growing aesthetics market with aggressive growth targets and direct commercial infrastructure.
Market
Galderma Raises Full-Year Guidance After Record First-Half Sales of $3.13B
Swiss aesthetics giant posts 24.6% YoY growth and lifts outlook, signaling strong demand across toxins and fillers despite market headwinds.
Market
Hugel Launches Letybo in India, Targets 9% Market Share by 2026
South Korean toxin maker enters India's high-growth botox market with aggressive expansion timeline.
Market
GLP-1 Aesthetic Care Market Projected to Reach $2B by 2030 — New Revenue Stream for Medspa Operators
Semaglutide and tirzepatide demand is creating a new aesthetic-adjacent category; practices are positioning to capture it.
Market
InMode Guides Q2 Revenue to $95.2M–$95.4M — Growth Resilience Amid Takeover Uncertainty
InMode's preliminary Q2 revenue guidance exceeds consensus, signaling sustained demand for RF and fractional-laser platforms despite acquisition turmoil.
Market
InMode Projects Q2 Revenue $95.2M–$95.4M, Reiterates $365M–$375M FY 2026 Guidance
InMode's steady revenue trajectory amid acquisition uncertainty signals continued device-market strength despite M&A noise.
Market
GLP-1 Aesthetic Care Market Projected to Hit $2B by 2030 — New Revenue Stream or Threat?
Aesthetic practices are capitalizing on GLP-1 demand, with the skincare-adjacent market expected to reach $2 billion within six years.
Market
Daewoong's Nabota Hits 1 Trillion Won in Sales — Korean Toxin Maker Accelerates U.S. and Global Expansion
A third-party neuromodulator gains traction as price competition reshapes the toxin market.
Market
GLP-1 Weight-Loss Boom Drives Post-Bariatric Body Contouring Surge — New Patient Pipeline for Medspas
Ozempic, Mounjaro adoption fuels demand for skin tightening and liposuction; practices report increased surgical referrals.
Market
InMode Guides Q2 2026 Revenue to $95.2M–$95.4M; Full-Year Outlook Holds at $365M–$375M
Device maker reiterates FY guidance despite takeover bid uncertainty; Q2 results due August 5.
Market
GLP-1 Weight-Loss Boom Drives Post-Reduction Body Contouring at Medspa Practices — New Revenue Stream Emerging
Practices are capitalizing on GLP-1 patient demand for non-surgical body tightening and skin quality treatments following significant weight loss.
Market
GLP-1 Weight-Loss Boom Fuels Body-Contouring Volume — Practices Report Surge in Post-Weight-Loss Procedures
Ozempic/Wegovy patients driving demand for skin-tightening and body-sculpting treatments.
Market
GLP-1 Weight Loss Boom Drives Post-Loss Body Contouring Demand at Aesthetic Practices
Ozempic and semaglutide uptake creates new patient flow for surgical and non-surgical body-sculpting procedures.
Market
Fotona4D Reports Surge in Younger Patient Bookings — 'Collagen Banking' Becomes 2026 Trend
Preventive aesthetic procedures drive growth among Gen Z and younger millennials seeking early intervention.
Market
Semaglutide Pricing at Medspas: Compounded vs. Branded and What Patients Actually Pay
Medspa semaglutide costs range from $200–$600+ per month depending on dose, formulation source, and markup strategy—here's how the margin model works and what drives patient pricing.
Market
Semaglutide Face: Why Medspa Owners Should Offer Fillers to GLP-1 Patients
GLP-1 weight loss drives facial volume loss. Here's how to capture that filler revenue—and why patients are primed to buy.
Market
Offering GLP-1 Weight Loss at a Medspa: Sourcing, Compliance, and Revenue Model
How to evaluate GLP-1 as a revenue line, manage sourcing and prescriber requirements, and stay compliant with state and federal regulations.
Market
GLP-1 Weight Loss Boom Drives 'Semaglutide Face' — Aesthetic Practices Report Surge in Volume Restoration Demand
Facial fat loss from GLP-1 drugs creates new patient cohort seeking filler and biostimulator treatments.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.